Alterity Therapeutics Files 6-K, Incorporates by Reference
Ticker: PRNAF · Form: 6-K · Filed: Sep 15, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, registration-statement, compliance
TL;DR
ALTERITY THERAPEUTICS LTD (ATHE) files 6-K, incorporating into S-8/F-3. Standard compliance.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on September 15, 2025, to incorporate by reference into its existing Registration Statements on Form S-8 and Form F-3. The filing includes Exhibit 99.1, a Notice Under Section 708A, which is a standard disclosure for foreign private issuers.
Why It Matters
This filing is a routine disclosure that incorporates previous filings into active registration statements, indicating ongoing compliance and potential for future share issuances.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previous documents and does not introduce new financial or operational information.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- September 15, 2025 (date) — Filing date
- Form S-8 (document) — Incorporated by reference into
- Form F-3 (document) — Incorporated by reference into
- Exhibit 99.1 (document) — Included in filing
- Notice Under Section 708A (document) — Content of Exhibit 99.1
FAQ
What is the purpose of this Form 6-K filing by Alterity Therapeutics Ltd.?
The Form 6-K is being filed to incorporate by reference into the company's existing Registration Statements on Form S-8 and Form F-3.
What specific exhibit is included with this Form 6-K?
The filing includes Exhibit 99.1, which is a Notice Under Section 708A.
What is the filing date of this Form 6-K?
The filing date is September 15, 2025.
Which registration statements are being updated by this filing?
This Form 6-K is being incorporated by reference into Alterity Therapeutics Ltd.'s Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
Is Alterity Therapeutics Ltd. a U.S. or foreign private issuer?
Alterity Therapeutics Ltd. is identified as a foreign private issuer, as indicated by the Form 6-K filing type and the checkmark next to 'Form 20-F'.
Filing Stats: 188 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2025-09-15 08:03:22
Filing Documents
- ea0257332-6k_alterity.htm (6-K) — 14KB
- ea025733201ex99-1_alterity.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-25-087423.txt ( ) — 44KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Notice Under Section 708A 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: September 15, 2025 2